Mylan Inc settles the patent litigation with Pfizer Inc. (NYSE:PFE) relating to the generic version of Celebrex. The Company filed the Abbreviated New Drug Application (ANDA) with the FDA for Celebrex capsules. The product primarily uses for the treatment of arthritis and pain management in adults. Pfizer Inc. (NYSE:PFE) net profit margin is 81.20% and weekly performance is 0.54%. On last trading day company shares ended up $29.76. Analysts mean target price for the company is $34.45. Pfizer Inc. (NYSE:PFE) distance from 50-day simple moving average (SMA50) is -1.63%.
Bristol-Myers Squibb Co (NYSE:BMY) gained after the company shared the results of an encouraging study on a combination treatment for patients with late-stage melanoma. Combining two different drugs in Bristol’s arsenal, Yervoy and nivolumab, the study observed the effects of the combo treatment, reporting 94% one-year survival rates and 88% two-year survival rates in the 127-person test. Bristol-Myers Squibb Co (NYSE:BMY) shares fell -0.65% in last trading session and ended the day on $47.21. Gross Margin is 72.40% and its return on assets is 8.00%. Bristol-Myers Squibb Co (NYSE:BMY) quarterly performance is -14.43%.
Merck & Co., Inc. (NYSE:MRK) has entered into an agreement with Dako, a subsidiary ofAgilent Technologies Inc. (NYSE:A) for developing diagnostic test to find cancer susceptibility. Merck & Co., Inc. (NYSE:MRK) shares moved up 0.29% in last trading session and was closed at $58.10, while trading in range of $57.72 – $58.47. Merck & Co., Inc. (NYSE:MRK) year to date (YTD) performance is 17.00%.
Medtronic, Inc. (NYSE:MDT) recently reported the receipt of CE (Conformité Européenne) Mark and the subsequent commercial launch of its Advisa and Ensura SR MRI SureScan single chamber pacemaker devices in Europe. Medtronic, Inc. (NYSE:MDT) ended the last trading day at $62.04. Company weekly volatility is calculated as 1.88% and price to cash ratio as 4.36. Medtronic, Inc. (NYSE:MDT) showed a positive weekly performance of 2.34%.
AstraZeneca Plc (ADR) (NYSE:AZN) is developing MEDI4736, an anti-PD-L1 monoclonal antibody. The company recently announced that it is jumping from a Phase 1 trial directly to a late-stage, Phase 3 trial in non-small cell lung cancer patients. In support of this decision was data in abstract #3001, which showed that in heavily pretreated solid tumor patients, three out of the 13 non-small cell lung cancer enrollees, or 23%, had partial responses. AstraZeneca plc (ADR) (NYSE:AZN) net profit margin is 8.00% and weekly performance is 1.33%. On last trading day company shares ended up $72.24. Analysts mean target price for the company is $72.53. AstraZeneca plc (ADR) (NYSE:AZN) distance from 50-day simple moving average (SMA50) is 1.84%.
Leave a Reply